Ilaria Lampronti
Overview
Explore the profile of Ilaria Lampronti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbari R, Bruggink V, Hofstetter R, Tupini C, Fagnani S, Baldini E, et al.
Antioxidants (Basel)
. 2024 Oct;
13(10).
PMID: 39456450
A current trend in healthcare research is to discover multifunctional compounds, able to interact with multiple biological targets, in order to simplify multi-drug therapies and improve patient compliance. The aim...
2.
Zuccato C, Cosenza L, Tupini C, Finotti A, Sacchetti G, Simoni D, et al.
Molecules
. 2024 Jan;
29(1).
PMID: 38202591
Induction of fetal hemoglobin (HbF) is highly beneficial for patients carrying β-thalassemia, and novel HbF inducers are highly needed. Here, we describe a new class of promising HbF inducers characterized...
3.
Tupini C, Zurlo M, Gasparello J, Lodi I, Finotti A, Scattolin T, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242574
Combined treatments employing lower concentrations of different drugs are used and studied to develop new and more effective anticancer therapeutic approaches. The combination therapy could be of great interest in...
4.
Ribeiro C, Higgs M, Muhlebach M, Wolfgang M, Borgatti M, Lampronti I, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902441
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new series of therapeutics that correct and potentiate some classes of mutations of the CFTR, have provided a great therapeutic advantage to...
5.
Baldisserotto A, Barbari R, Tupini C, Buzzi R, Durini E, Lampronti I, et al.
Antioxidants (Basel)
. 2023 Feb;
12(2).
PMID: 36829968
This research investigated plant extracts as a source of potential new actives in the nutritional, cosmetic, and pharmaceutical fields. which is extensively known for its nutritional properties, has been investigated...
6.
Barbari R, Tupini C, Durini E, Gallerani E, Nicoli F, Lampronti I, et al.
Molecules
. 2023 Jan;
28(1).
PMID: 36615480
A current trend of research in the health field is toward the discovery of multifunctional compounds, capable of interacting with multiple biological targets, thus simplifying multidrug therapies and improving patient...
7.
Zuccato C, Cosenza L, Zurlo M, Breveglieri G, Bianchi N, Lampronti I, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36614221
The human homologue of mouse Ly-1 antibody reactive clone protein (LYAR) is a putative novel regulator of γ-globin gene transcription. The LYAR DNA-binding motif (5′-GGTTAT-3′) is located within the 5′-UTR...
8.
Tupini C, Chilin A, Rossi A, De Fino I, Bragonzi A, DAversa E, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430961
A series of new-generation TMA (4,6,4'-trimethyl angelicin) analogues was projected and synthetized in order to ameliorate anti-inflammatory activity, with reduced or absent toxicity. Since the NF-κB transcription factor (TF) plays...
9.
Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening
Vaccarin C, Gabbia D, Franceschinis E, De Martin S, Roverso M, Bogialli S, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232826
A small library of new angelicin derivatives was designed and synthesized with the aim of bypassing the side effects of trimethylangelicin (TMA), a promising agent for the treatment of cystic...
10.
Prosdocimi M, Zuccato C, Cosenza L, Borgatti M, Lampronti I, Finotti A, et al.
Wellcome Open Res
. 2022 Sep;
7:150.
PMID: 36110836
Drug repositioning and the relevance of orphan drug designation for β-thalassemia is reviewed. Drug repositioning and similar terms ('drug repurposing', 'drug reprofiling', 'drug redirecting', 'drug rescue', 'drug re-tasking' and/or 'drug...